Condition of increased blood pressure within the arteries of the lungs
POPULARITY
46 episodes with Pulmonary hypertension
24 episodes with Pulmonary hypertension
7 episodes with Pulmonary hypertension
6 episodes with Pulmonary hypertension
15 episodes with Pulmonary hypertension
5 episodes with Pulmonary hypertension
10 episodes with Pulmonary hypertension
4 episodes with Pulmonary hypertension
10 episodes with Pulmonary hypertension
Analyzing Trump's plan to roll back soaring drug prices for Americans; Sports bras eliminate bounce but may take a toll on women's backs; RFK Jr. targets the chemicals in our food; Do Americans really eat more animal protein than any other of the world's nations? Causes and treatments for pulmonary hypertension.
What is the best method to heal a urinary tract infection?What is the difference between hypertension and pulmonary hypertension?I have osteoporosis and take Warfarin. How can I support my bone health?Would you put someone with my lipid profile on a statin?Would urolithin A help increase my energy? Or must I succumb to age limits?
In the final part of this series, Joseph Parambil, MD, walks us through the approach of managing pulmonary hypertension, reviews the pathophysiology and digs into the mechanisms and the differences in the medications. Intro 0:12 In this episode 0:17 Interview with Joseph Parambil, MD 2:53 Reviewing and clarifying pathophysiology prior to initiating therapeutics 4:13 Evaluating patients in terms of their functional status and how does that play a role in initiating therapies 4:25 Vasoreactivity testing 10:21 The categories of medications 14:40 Endothelin receptor antagonists 37:07 TGF pathway 42:13 Scleroderma patient and treatment 50:19 Do patients get a repeat right-heart catheterization? 55:51 What about the TGF-beta? 56:55 Thank you, Dr. Parambil 58:34 Thanks for listening 59:17 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Disclosures: Brown and Parambil report no relevant financial disclosures. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic's Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine.
Send us a textResponse to Inhaled Nitric Oxide and Mortality Among Very Preterm Neonates With Pulmonary Hypertension.Baczynski M, Weisz D, Thomas L, Fevrier S, Castaldo M, Soraisham A, Hyderi A, Agarushi R, Bhattacharya S, Lalitha R, Sidhu A, Abdul Wahab MG, Altit G, Hébert A, Louis D, Elsayed Y, Mitra S, Deshpande P, Kharrat A, Zhu F, Ting J, Yoon E, Shah PS, Jain A; Canadian Neonatal Network Investigators.JAMA Netw Open. 2025 Feb 3;8(2):e2458843. doi: 10.1001/jamanetworkopen.2024.58843.PMID: 39928335 Free PMC article.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
On this episode of JHLT: The Podcast, the Digital Media Editors invite author Ioana Preston, MD, to discuss the paper, “Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.” Dr. Preston is the director of the pulmonary hypertension center at Lahey Hospital and Medical Center in Burlington, Massachusetts, and has over 20 years of experience in caring for patients with PH, as well as multiple clinical trials in PH. The episode explores: What makes sotatercept unique as the first “biologic” in the treatment of PAH Hypotheses about the mechanism of action in sotatercept Sotatercept's interaction with mPAP and what it indicates about the drug's action on the pulmonary vasculature For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Those involved in the heart failure and mechanical circulatory support should tune in again later this month for a study on apixaban plasma levels in patients with HeartMate 3 support. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension. Intro 0:12 In this episode 0:18 Recap of part 1 & 2 0:31 What part 3 is about 2:31 WHO conference in 1975: Treating pulmonary hypertension 3:48 The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1 5:20 Epoprostenol 6:18 Prostacyclin 10:37 Endothelin antagonists 11:41 Phosphodiesterase type 5 (PDE5) inhibitors 14:08 Interaction of nerves and blood vessels 15:06 The Soups VS the Sparks 17:36 A dreamed experiment 19:06 Acetylcholine 23:23 Enter “the calabar bean” 24:45 Acetylcholine and vasodilation: 1976 26:01 Rabbit aorta 27:45 Nitric oxide 29:38 Why are we using nitric oxide to treat pulmonary hypertension? 31:31 Tachyphylaxis 33:48 TNT factories 35:09 Nitrous oxide and tachyphylaxis 36:52 Pfizer in the 1980s 38:06 Understanding the trigger of pulmonary hypertension 40:53 PDE5 and nitric oxide and pulmonary hypertension 43:07 The end of the ripping yarns 44:20 Coming up in part 4 46:17 Thanks for listening 47:29 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bernard C. C R Soc Biol. 1851;3:163-164. Furchgott RF, et al. Nature. 1980;doi:10.1038/288373a0. Galiè N, et al. N Engl J Med. 2005;doi:10.1056/NEJMoa050010. Ghofrani HA, et al. Nat Rev Drug Discov. 2006;doi:10.1038/nrd2030. Giordano D, et al. Biochim Biophys Acta. 2001;doi:10.1016/s0167-4889(01)00086-6. Guthrie F. Q J Chem Soc. 1859;doi:10.1039/QJ8591100245. Higenbottam T, et al. Lancet. 1984;doi:10.1016/s0140-6736(84)91452-1. Marsh N, et al. Clin Exp Pharmacol Physiol. 2000;doi:10.1046/j.1440-1681.2000.03240.x. Montastruc JL, et al. Clin Auton Res. 1996;doi:10.1007/BF02281906. Nejad SH, et al. Future Cardiol. 2024;doi:10.1080/14796678.2024.2367390. Tansey EM. C R Biol. 2006;doi:10.10116/j.crvi.2006.03.012. Warren JV. Trans Am Clin Climatol Assoc. 1988;99:10-6. Disclosures: Brown reports no relevant financial disclosures.
Sandra M. Oliver-McNeil, DNP, ACNP-BC, FACC, JACC: Case Reports Deputy Editor, is joined by author Liam S. Flanagan, MD discussing this study from Flanagan et al presented at ACC.25 and published in JACC: Case Reports. Pulmonary arterial hypertension (PAH) has a diverse range of etiologies and carries significant morbidity and mortality. Here, a 45-year-old female presented with shortness of breath and was found to be in acute right heart failure due to PAH. Exam demonstrated features of scurvy. She initially required vasopressors, supplemental oxygen therapy, and PAH therapies but rapidly improved with vitamin C supplementation.
Returning for a second study this month, the JHLT Digital Media Editors conduct an internal discussion on the paper, “Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.” The episode explores: The aging PAH population and the new comorbidities that must be considered in research How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension Limitations on the study and opportunities for future research For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Those on lung transplant teams should check the previous episode for a study on how rewarming ischemia time affects lung transplant outcomes. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
Jimmy Ford, MD discusses the 7th World Symposium on Pulmonary Hypertension and his work on the Exploring the Patient Perspective in PH Task Force. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @UNCDeptMedicine
In this episode, we review the high-yield topic Pulmonary Hypertension from the Pulmonary section at Medbullets.comFollowMedbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Pulmonary Hypertension from the Respiratory section.FollowMedbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In part 2, we dig into the history of pulmonary hypertension. How did this strange diagnosis first get recognized, what does it have to do with cows with thick necks and urinary catheters in the heart? Intro 0:11 In this episode 0:17 Recap of part 1 0:26 How was pulmonary hypertension discovered? 2:38 1891 3:51 1901 5:07 1935 7:02 Hilar dance 12:58 Cardiac catheterization: 1929 15:03 When did cardiac catheterization become relevant? 20:10 1965: Aminorex 24:40 World Health Organization: 1975 26:37 1980s: toxic oil syndrome of Spain 28:20 Preview of part 3 33:15 Back to cardiac catheterization 34:08 Briskets disease 35:45 1947 37:56 Pulmonary physiology and prostaglandin therapies (in the next episode) 38:41 Schistosomiasis outbreaks in Egypt 1938 40:26 Chronic thromboembolism 45:03 Thanks for listening 48:16 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Barst RJ. Ann Thorac Med. 2008;doi:10.4103/1817-1737.37832. Bodo R. J Physiol. 1928;doi:10.1113/jphysiol.1928.sp002447. Dresdale DT, et al. Am J Med. 1951;doi:10.1016/0002-9343(51)90020-4. Egypt. Stanford.edu. Published 2015. https://schisto.stanford.edu/pdf/Egypt.pdf. Hewes JL, et al. Pulm Circ. 2020;doi:10.1177/2045894019892801. Johnson S, et al. Am J Respir Crit Care Med. 2023;doi:10.1164/rccm.202302-0327SO. Newman JH. Am J Respir Crit Care Med. 2005;doi:10.1164/rccm.200505-684OE. Weir EK, et al. Circulation. 1996;doi:10.1161/01.cir.94.9.2216. Disclosures: Brown reports no relevant financial disclosures.
Jody shares what he learned at this year's Huntsville Hospital Cardiology Update, held on Saturday, February 8th, 2025 at the UA Huntsville College of Nursing.Links:1) UA Huntsville CON Golden Gala2) WHO 2003 Pulmonary Hypertension Guidelines3) BMPR2 Gene Mutations4) 2022 ESC/ERS 3 Strata Risk Score Calculator for Pulmonary Hypertension
In this episode of the Medicine Grand Rounders, Dr. Chaisson goes over the pathophysiology, diagnosis and management of pulmonary hypertension.
In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up! Intro 0:11 In this episode 0:16 Preview of the four-part series 4:46 Interview with Joseph Parambil, MD 6:27 How did you become interested in pulmonary hypertension? 7:02 Brown and Parambil discuss the histology of pulmonary hypertension. 10:13 Brown and Parambil discuss a case of pulmonary hypertension. 12:26 What is pulmonary hypertension and what does that mean for a rheumatologist? Where is pulmonary hypertension happening? 13:25 Describe the different groups of pulmonary hypertension. 19:51 A note about Dr. Chatterjee 20:25 Brown and Parambil discuss the groups of pulmonary hypertension. 23:35 What should we know about evaluating patients with pulmonary hypertensions? 26:51 Brown and Parambil discuss bendopnea and other signs of pulmonary hypertension. 29:58 What about the heart sound? 33:06 What should we look for in patients who we suspect to have pulmonary hypertension? 36:52 What should we look for in the tricuspid jet? 38:18 Brown and Parambil discuss the use of echocardiograms in pulmonary hypertension. 39:28 Tell us about the threshold of diagnosis. 40:47 What is the difference between the mean pressure and the wedge pressure? 41:41 What about the role of the pulmonary function test? 43:55 Summary 46:41 Do you think the pulmonary hypertension in scleroderma and lupus are different entities? 48:37 Brown and Parambil discuss the connection of autoimmune disease and pulmonary hypertension. 50:49 Coming up in episode 91 51:50 Thanks for listening 52:25 Disclosures: Brown and Parambil report no relevant financial disclosures. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic's Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
Dr. Hunter Champion received his training in Cardiovascular Disease, Heart Failure and Transplant Cardiology at Johns Hopkins where he later directed the Bernard Laboratory for the Study of Cardiovascular Disease. Thereafter he was recruited to the University of Pittsburgh to join the faculty of the Divisions of Pulmonary, Allergy and Critical Care Medicine and the Cardiovascular Institute as an Associate Professor of Medicine where he directed Translational Research for the University of Pittsburgh Vascular Medicine Institute. He is a Heart Failure trained specialist and a Pulmonary Hypertension trained specialist and treats patients with hypertension, coronary artery disease, heart rhythm issues, and valvular disease. Dr. Champion joins Mark Immelman on the #OntheMark podcast to introduce 5 lifestyle changes that are sure to lead to a healthier, happier existence - habits which will also set you on the path to better physical performance and, by extension, better golf. Dr Champions elaborates on: Healthy body movement High quality sleep Morning sunlight, fresh air and breathwork The practice of gratitude, and Healthier eating involving protein and green vegetables. He also talks about the 'mind-body connection', alcohol consumption, managing stress, hydration, dietary supplements, meditation, hot and cold water therapy and grounding. Download this podcast or watch it on YouTube - search and subscribe to Mark Immelman.
CME credits: 0.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-diagnosis-management-and-updates-chairpersons-perspective/26626/ During a satellite symposium at the AHA 2024 Annual Meeting, experts reviewed the role of novel disease-modifying therapies (DMTs) in treating and managing pulmonary hypertension (PH) and the impact of current PH treatments vs novel DMTs. They also discussed how to identify appropriate patients for DMTs and strategies to customize treatment with risk-based assessments. In addition, highlights from the 7th World Symposium in PH were discussed. Tune in to keep up! =
CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-comorbidities-with-pah-and-group-2-ph/28869/ Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from left heart disease may further complicate diagnosis and treatment. Hear what the experts have to say about identifying and treating these patient populations. =
CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-management-practice-trends-and-updates/28868/ The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.=
CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-in-pulmonary-hypertension-practice-trends-and-updates/28867/ Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You'll also discover changing practice trends and the latest evidence that may impact your practice. =
Send us a textIn this episode of the Incubator, hosts Betsy Crouch and David McCulley welcome Dr. Judy Aschner, a prominent neonatologist and physician scientist. Dr. Aschner shares her journey building a research career and emphasizes the importance of mentorship, determination, and collaboration across disciplines. She discusses her personal experiences that shaped her research focus, particularly in pulmonary hypertension and environmental health in neonatology. The conversation highlights the challenges and triumphs of a career in medical research, underscoring the significance of intellectual curiosity and the impact of personal experiences on professional paths. Dr. Judy Aschner discusses her groundbreaking research on manganese levels in parenteral nutrition and its uptake into the brain of infants with prolonged exposure to TPN. She highlights the importance of understanding metal environmental exposures in the NICU and the collaborative efforts that led to successful grant writing for research projects. Dr. Aschner emphasizes the need for inclusivity in research, particularly for children with disabilities, and the significance of longitudinal studies in assessing long-term health outcomes. Additionally, she shares her passion for rock climbing as a means of maintaining mental and physical health amidst her demanding career.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Chronic Thrombo-Embolic Pulmonary Hypertension Guest: Robert P. Frantz, M.D. Host: Kyle Klarich, M.D. In this episode, the experts discuss chronic thrombo-embolic pulmonary hypertension. Chronic thromboembolic pulmonary hypertension results from unresolved emboli in the lungs, causing increased resistance, right heart strain, and shortness of breath. Listeners will learn more about three different treatments available, including surgery, balloons, and medication. Topics Discussed: What is chronic thromboembolic pulmonary hypertension? What are the surgical treatments of chronic thromboembolic pulmonary hypertension? Are there other treatments available? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.
In today's VETgirl online veterinary CE podcast, we discuss hypocoagulability in dogs with pulmonary hypertension. For quick review, pulmonary hypertension, which we will refer to as “PH”, is an abnormal increase in pulmonary pressure and can be caused from cardiac, respiratory, or systemic conditions. In human medicine, both hyper- and hypocoagulability have been associated with PH, but no veterinary studies have been performed on this topic... until now! So today we will be reviewing the AJVR retrospective study by Min et al entitled “Pulmonary Hypertension is Associated with Hypocoagulability in Dogs: A Retrospective Analysis of 66 Cases (2013-2021).”
Hall Skaara, a resilient PH patient and founder of the Norwegian Association for Pulmonary Hypertension, recounts his 19-year journey living with idiopathic pulmonary hypertension. He shares how he transformed the challenges of the pandemic into an innovative opportunity by helping create the Bel Air Center, a virtual global PH community space. The Bel Air Center aims to foster global connections, support, and resources for patients, caregivers, and healthcare professionals. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @EuropePHA
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this podcast episode, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.This podcast aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.Launch Date: November 19, 2024Release Date: November 19, 2024Expiration Date: October 31, 2025FACULTYJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiOksana Shlobin, MDMedical Director, Pulmonary Hypertension ProgramDirector of Education and Outreach, Advanced Lung Disease ProgramInova Fairfax HospitalThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-pah-updates-from-the-7th-world-symposium-on-pulmonary-hypertension-1
In this episode, Dr. Valentin Fuster reviews a recent study exploring the clinical overlap between heart failure with preserved ejection fraction (HFpEF) and Group 1 pulmonary hypertension. The study identifies a subset of patients with pulmonary hypertension who have a higher risk of heart failure and worse outcomes, emphasizing the need for further investigation into whether pulmonary hypertension therapies could improve prognosis in these patients.
As part of the October issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews associate editor Marius Hoeper and Kelly Chin (UT Southwestern Medical Center, Dallas, TX, USA) about articles published from the World Symposium on Pulmonary Hypertension.
CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.=
CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/updates-from-the-7th-world-symposium-task-force/24597/ The 7th World Symposium Task Force on Pulmonary Hypertension focused on the standard of care, best practices, and emerging clinical data in the treatment of pulmonary hypertension (PH). For the first time, the 2024 Symposium started with patients' perspectives, acknowledging the respect and importance that should be given to patients' priorities. The translational aspects of modern pulmonary vascular research were highlighted, as were transplantation, bridging and support technologies, palliative care, management of pregnant women with PH, specificities of pediatric care, and the benefits of emerging multimodality imaging techniques and novel technologies. Tune in to get the details and improve care for your patients today! =
In this episode, we follow the story of Jessica, a diligent bank employee in her forties who, during a routine check-up, learns she has pulmonary hypertension, a condition characterized by high pressure in the arteries of the lungs. Initially, Jessica's symptoms of fatigue and shortness of breath seemed minor, but they were soon linked to an underlying issue: sleep apnea. Through a detailed treatment plan involving CPAP therapy, dietary changes, weight management, smoking cessation, and improved sleep hygiene, Jessica begins her journey toward better health. Her experience highlights the crucial role of regular health screenings, early detection, and lifestyle modifications in managing and overcoming medical conditions.
Commentary by Dr. Zhi-Cheng Jing
Send us a Text Message.In this episode of "The Incubator" at NeoHeart 2024, hosts Ben and Daphna interview Dr. Sam Gentle, a neonatologist presenting at the conference.Dr. Gentle discusses his upcoming talk on the potential impact of patent ductus arteriosus (PDA) on the progression of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension. He emphasizes the lack of pulmonary hypertension as an outcome in previous PDA trials and the importance of considering PDA as a continuous exposure rather than a binary one.The conversation touches on the challenges of determining when to intervene in cases of prolonged PDA exposure. Dr. Gentle shares insights from his research, suggesting that PDA exposure beyond 2-3 months may significantly increase the risk of pulmonary hypertension in premature infants.They discuss the cognitive biases that can affect clinical decision-making regarding PDA treatment and the need for statistical analysis to guide interventions. Dr. Gentle also mentions an upcoming trial on percutaneous PDA closure that will assess pulmonary hypertension as an outcome.The episode highlights the ongoing debate in neonatology regarding PDA management, particularly the question of how long is too long to leave a PDA open. Dr. Gentle appreciates the conference's multidisciplinary approach, noting the value of gaining perspectives from cardiologists on these complex issues As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
This recording features audio versions of August 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Safety and Effectiveness of Endovascular Treatment of Complications Associated with Persistent Sciatic Artery: A Qualitative Systematic Review ReadA Qualitative Systematic Review of Endovascular Management of Renal Artery Aneurysms ReadHemorrhagic Adverse Events of Transthoracic Needle Biopsy of the Lung in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis ReadRecurrence of Pulmonary Arteriovenous Malformation after Embolization in Patients with Pulmonary Hypertension ReadClinical, Functional, and Quality-of-Life Outcomes after Computer Assisted Vacuum Thrombectomy for Pulmonary Embolism: Interim Analysis of the STRIKE-PE Study ReadSafety and Effectiveness of Track Cauterization for Lung Cryoablation ReadComparison of Outcomes of Drug-Coated Balloons versus Plain Balloons in Secondary Interventions on Percutaneous Arteriovenous Fistulae ReadTransperineal Laser Ablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Long-Term Follow-Up in 40 Patients ReadJVIR and SIR thank all those who helped record this episode:Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineAbstract readers:Vasan Jagadeesh, University of California San Diego School of MedicineDhanush Reddy, MBBS, Massachusetts General HospitalAshwin Mahendra, Florida Atlantic University Charles E. Schmidt College of MedicineTaji Kommineni, MD, JD, LLM, Emory UniversityAnna Hu, George Washington University School of Medicine and Health SciencesBrian Ng, MD, University of California Los AngelesJack Ficke, Frank H. Netter School of MedicineMark Oliinik, Loma Linda University School of Medicine© Society of Interventional RadiologySupport the Show.
Send us a Text Message.Cardiopulmonary physiological effects of diuretic therapy in preterm infants with chronic pulmonary hypertension.Zhu F, Ibarra Rios D, Joye S, Baczynski M, Rios D, Giesinger RE, McNamara PJ, Jain A.J Perinatol. 2023 Oct;43(10):1288-1294. doi: 10.1038/s41372-023-01742-0. Epub 2023 Aug 7.PMID: 37550529As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Send us a Text Message.Patent Ductus Arteriosus and Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Bayesian Meta-Analysis.Villamor E, van Westering-Kroon E, Gonzalez-Luis GE, Bartoš F, Abman SH, Huizing MJ.JAMA Netw Open. 2023 Nov 1;6(11):e2345299. doi: 10.1001/jamanetworkopen.2023.45299.PMID: 38015504 Free PMC article.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Send us a Text Message.Vasopressin in newborns with refractory acute pulmonary hypertension.Ouellet S, Drolet C, Morissette G, Pellerin A, Hébert A.Pediatr Res. 2024 May;95(6):1572-1577. doi: 10.1038/s41390-023-02995-3. Epub 2024 Jan 11.PMID: 38212386As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
In this episode, Dr. Dunbar Ivy, a pediatric cardiologist at the University of Colorado, discusses the upcoming World Symposium on Pulmonary Hypertension, where experts from around the world will gather to discuss the progress made and future directions. Dr. Ivy highlights the work of the pediatric pulmonary hypertension task force, which aims to develop expert opinions on various topics, including the role of different therapies for patients who have failed all available medical treatments. The task force also focuses on understanding genetic abnormalities and developmental lung disorders, defining pulmonary hypertension in neonates, and addressing the challenges of clinical trials for pediatric patients.The task force plans to publish their findings in 2024 and welcomes feedback from the medical community. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD #PPHNet @PPHNet
On this episode of JHLT: The Podcast, the JHLT Digital Media Editors explore two studies from the June issue of The Journal of Heart and Lung Transplantation. Digital Media Editor Van-Khue Ton, MD, a transplant cardiologist from Massachusetts General Hospital, hosts this episode. First, Dr. Ton and Digital Media Editor Marty Tam, MD, interview their first guests, first author Matthew Carey, MD, MBA, and senior author Justin Fried, MD, both of the Columbia University Irving Medical Center in New York City, on their study “Aortic Root Thrombosis in patients with HeartMate 3 left ventricular assist device support.” This retrospective study of all patients receiving a HeartMate 3 LVAD at a single center between November 2014 and August 2020. The study evaluated findings related to patients with aortic root thrombosis, classified as having at least 1 echocardiogram or contrast-enhanced CT scan with thrombus. In the population of 197 patients, 19 had aortic root thrombus, which was ultimately associated with an increased risk of developing significant aortic regurgitation during the study period. Drs. Carey and Fried discuss whether aortic valve opening is associated with increased risk of aortic root thrombus, how to balance the bleeding-thrombosis scale in patients, and how the study fits in the context of prior generations of LVAD. Next, Dr. Ton joins and Digital Media Editor Erika Lease, MD, FCCP, to interview, Jacqueline DesJardin, MD, a Fellow in the department of medicine at the University of California San Francisco. Dr. DesJardin is first author on the study “Investigating the “sex paradox” in pulmonary arterial hypertension: Results from the Pulmonary Hypertension Association Registry (PHAR).” PHAR is a multicenter US-based registry of patients with PAH, and this study analyzed 1,891 patients from the registry, 1,425 (75%) of whom were female. At baseline, compared to men, women had worse functional status and worse hemodynamics. Women were more likely to be on triple therapy or parenteral prostacyclin therapies at baseline. Interestingly, women had better survival than men, even after adjusting for numerous variables. In the discussion, Dr. DesJardin explains what collider stratification bias is, and how it may illuminate the complex epidemiological system that creates this disparity. She shares the three potential causal models posed in the study, and considers how the study might be followed up. Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
In this episode, Dr. Eric Austin, a pediatric pulmonologist and pulmonary hypertension doctor, discusses the upcoming World Symposium on Pulmonary Hypertension, which will focus on various aspects of pulmonary hypertension research and clinical care. Dr. Austin is part of the task force on genetics and genomics, which aims to explore the genetic landscape of pulmonary hypertension and identify opportunities for future research and therapy development. He highlights the significance of the discovery of the BMPR2 gene and its role in pulmonary arterial hypertension (PAH), leading to the development of the gene-informed therapy sotatercept. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD #PPHNet @PPHNet @VUMCchildren
Expert researcher and clinician, Dr. Elana Bernstein, is our guest this week as we dive into lung disease brought on by Systemic Sclerosis (SS). We discuss symptoms, diagnosis, how systemic sclerosis affects the lungs, including pulmonary hypertension and interstitial lung disease. Dr. Bernstein, who has dedicated her career to improving patient outcomes in systemic sclerosis, explains her approach to screening for lung disease, plus the latest research and questions that need to be answered.
Commentary by Dr Jia-Ling Lin
AFR Case Studies Pulmonary Hypertension by Albuquerque Fire Rescue
Drs Michelle Kittleson and Ronald Oudiz dive into everything cardiologists need to know about the diagnosis and treatment of pulmonary hypertension. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/997320). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Heart Failure https://emedicine.medscape.com/article/163062-overview Pulmonary Arterial Hypertension https://emedicine.medscape.com/article/303098-overview Cardiac Catheterization in Pulmonary Hypertension: Doing It Right, With a Catheter on the Left https://pubmed.ncbi.nlm.nih.gov/33224785/ How to Initiate and Uptitrate GDMT in Heart Failure: Practical Stepwise Approach to Optimization of GDMT https://pubmed.ncbi.nlm.nih.gov/36456074/ Phosphodiesterase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK559276/ Cardiovascular Biology of Prostanoids and Drug Discovery https://pubmed.ncbi.nlm.nih.gov/32295420/ Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease https://pubmed.ncbi.nlm.nih.gov/21606405/ Pulmonary Hypertension Association https://phassociation.org/
In this episode, we review the high-yield topic of Pulmonary Hypertension Drugs from the Pulmonary section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Normal blood pressure keeps us alive. It's the force that moves blood throughout our circulatory system, ensuring that oxygen and nutrients reach our organs and tissues and that waste products are eliminated. When we hear the word hypertension—high blood pressure—we know this describes the blood flow exerting too much force against blood vessel walls. Pulmonary hypertension describes high blood pressure in the vessels of the lung. Specifically, pulmonary hypertension is an elevated mean arterial pressure (≥20 mm Hg at rest) of the vessels between the heart and the lung. After listening to this AudioBrick, you should be able to: Define pulmonary hypertension and compare with pulmonary arterial hypertension. Describe the clinical presentation and diagnosis of pulmonary hypertension, including results from electrocardiogram, echocardiogram, and heart catheterization. Explain how pulmonary hypertension leads to right-sided heart failure. Describe how pulmonary vascular resistance affects pulmonary arterial pressure. List common etiologies of pulmonary hypertension, differentiating between cardiac and pulmonary causes. List the most common cause of pulmonary arterial hypertension. Describe the treatment of pulmonary hypertension. You can also check out the original brick on Pulmonary Hypertension from our Respiratory collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks. After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts. It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/
SPECIAL EDITION: Jonathan Hudson is a Global Trial Leader in Pulmonary Hypertension at Janssen Research & Development and is accompanied by colleague Josephine Garcia-Ferrer, Ph.D and Medical Manager. Jonathan and Josephine discuss Pulmonary Arterial Hypertension (PAH), the importance of clinical trials, what they entail, and share information on Janssen's UNISUS Study for adults with PAH. Learn more about UNISUS Study with the Janssen Global Trial Finder. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com
What happens when high blood pressure reaches inside your lungs? The changing treatments for pulmonary hypertension. Meet one young woman hoping new medicine will help reclaim her life.
Dr. Kathryn del Valle has a conversation with Dr. Hilary DuBrock about Pulmonary Hypertension fellowship, including what it entails, who is eligible to apply, and why it can be beneficial for those pursuing a career in PH.
Pulmonary Hypertension Part II Special Guest: Zach Smith, PharmD, BCPS, BCCCP, FCCP 04:03 – Intro/Diagnosis/Classification 14:30 – Treatment overview 24:00 – CCB 30:30 – PDE5i/ERA/GCS 40:00 – Prostacyclins 46:40 – RV failure in the ICU 64:30 – Role of PharmD/Take-home points Reference List: https://pharmacytodose.files.wordpress.com/2023/10/pulmonary-hypertension-part-ii-references.pdf PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode, we're exploring the key things a nurse needs to know about pulmonary hypertension (PH). This condition affects the blood vessels in the lungs and can have serious implications on cardiac function. In this episode, we'll explore: Different subgroups of pulmonary hypertension Underlying causes of PH Signs and symptoms associated with PH Key diagnostic tests utilized to diagnose and evaluate a patient with PH Treatments and lifestyle modifications Important patient education components Whether you're a nursing student or an experienced healthcare professional, this episode will provide you with valuable insights into understanding and caring for patients with pulmonary hypertension. So hit play and let's dive into pulmonary hypertension together! __________ Full Transcript - Read the article and view references. FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Study Sesh - Change the way you study with this private podcast that includes dynamic audio formats that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh! Med Surg Solution - Are you looking for a more effective way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics and out-of-this-world study guides. LATTE Method Template - Download the free LATTE Method Template so you can streamline how you study and focus on what a nurse needs to know.
© 2020-2025 Ivy Podcast Discovery LLC
